633 A Phase 1a/1b, dose-escalation/dose-expansion study of NPX267 in subjects with solid tumors known to express HHLA2

• Patrick Forde,
• Aung Naing,
• David F McDermott,
• Leena Gandhi,
• Melissa Johnson,
• Justin Gainor,
• Yuan Ji,
• Haiying Cheng,
• Ismael Rodriguez Rivera

Affiliations

Patrick Forde

Aff3 grid.21107.350000000121719311Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore MD USA

Aung Naing

Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

David F McDermott

5Beth Israel Deaconess Medical Center, Boston, MA, USA

Leena Gandhi

Aff9 0000 0004 1936 8753grid.137628.9Department of MedicineNew York University, Perlmutter Cancer Center, NYU School of Medicine 10016 New York NY USA

Melissa Johnson

Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, USA

Justin Gainor

6Massachusetts General Hospital, Boston, MA, USA

Yuan Ji

Department of Pathology, Zhongshan Hospital Fudan University, Shanghai, China

Haiying Cheng

2Montefiore Medical Center, New York, NY, USA

Ismael Rodriguez Rivera

2NEXT Oncology, San Antonio, TX, USA